Aenova Expands Production Capacities in Germany
The construction of a new production building of over 3,100 m2 on the company premises started in April 2020. The start of operations is planned for mid-2021.
Aenova Group, at the beginning of this year, decided to expand the production capacities at the Tittmoning, Germany site, in order to meet the constantly growing demand for pharmaceuticals. According to Aenova, the investment volume for the first of three planned expansion stages amounts to €25 million. More than 100 new jobs are to be created when the last expansion stage is reached.
In Tittmoning the company Dragenopharm Apotheker Püschl, which belongs to Aenova, produces and distributes tablets and capsules for international pharmaceutical and health care companies.
The construction of a new production building of over 3,100 m2 on the company premises started in April 2020 in cooperation with Marianne Greither, the site owner. The start of operations is planned for mid-2021.
"Pharmaceutical contract manufacturing plays a decisive role in supplying the population with drugs and food supplements. One of these 'silent players' behind the big, well-known pharmaceutical companies is the Aenova Group", explains Jan Kengelbach, the group’s CEO.
With over 4,300 employees, the company manufactures at 15 locations for almost all renowned pharmaceutical companies worldwide. "In Tittmoning, our largest site, we are again investing in ultra-modern production capacities after several successful expansion projects. This is part of our growth strategy, which is being continued at other locations", Kengelbach added.
With around 630 employees, the Tittmoning site produced 7.5 billion tablets last year for more than 100 customers worldwide. With the expansion project, an annual capacity of over 10 billion tablets will be achieved in the future, said Helmut Stibich, head of the Tittmoning site.
